ʻOi aku ka nui o ke kaumaha ma luna o nā loulou Tirzepatide i ʻehiku mau mea

Ma waena o ka 3188 poʻe me ka maʻi maʻi type 2 i mālama i kā lākou tirzepatide (Mounjaro, Lilly) regimen i ʻehā mau hoʻokolohua pivotal o ka luna, ua loaʻa i kahi hapaha ka liʻiliʻi he 15% ʻoki ʻia mai ko lākou kaumaha kino ma hope o 40-42 mau pule o ka mālama ʻana, a ua loaʻa i nā mea noiʻi ʻehiku mau kumu hoʻololi i hoʻopili nui ʻia me kahi kiʻekiʻe o kēia pae o ke kaumaha.

"Ke kōkua nei kēia mau ʻike i ka hoʻomaopopo ʻana i ka poʻe me ka maʻi maʻi type 2 e loaʻa paha i ka hoʻemi ʻana i ke kaumaha o ke kino me ka hoʻomaikaʻi ʻana i nā mea pilikia cardiometabolic me tirzepatide," wahi a nā mea kākau.

HANA:

• Ua alakaʻi nā mea noiʻi i ka nānā ʻana o ka ʻikepili i hōʻiliʻili ʻia mai ka huina o 3188 poʻe me ka maʻi maʻi type 2 i mālama i kā lākou tirzepatide regimen i hāʻawi ʻia no 40-42 mau pule i loko o kekahi o nā hoʻokolohua pivotal ʻehā o ka luna: SURPASS-1, SURPASS- 2, SURPASS-3, a me SURPASS-4.
• Ua manaʻo ka poʻe noiʻi e ʻike i nā wānana o ka hoʻemi ʻana o ke kaumaha o ke kino ma kahi o 15% me ka mālama ʻana i ka tirzepatide ma kekahi o nā ʻekolu i hoʻāʻo ʻia - 5 mg, 10 mg, a i ʻole 15 mg - i lawelawe ʻia e ka subcutaneous injection i hoʻokahi pule.
• ʻO nā hoʻāʻo ʻehā a pau i hāʻawi i ka ʻikepili i pāpā ʻia i ka lāʻau like ʻole e hāpai i ka pohō kaumaha, a ʻaʻole i loaʻa i nā poʻe i komo i loko o ka loiloi nā lāʻau hoʻopakele no ka mālama ʻana i ka glycemia.
• ʻO ke ana kūpono mua ma nā haʻawina ʻehā ʻo ka hiki o tirzepatide ke hoʻomaikaʻi i ka mana glycemic (ana ʻia e ka pae A1c) i hoʻohālikelike ʻia me kahi placebo, semaglutide (Ozempic) 1 mg SC i hoʻokahi pule i kēlā me kēia pule, insulin degludec (Tresiba, Novo Nordisk), a i ʻole insulin glargine ( Basaglar, Lilly).

LAWE AKU:

• Ma waena o ka poʻe 3188 i hoʻomau i kā lākou tirzepatide regimen no 40-42 mau pule, 792 (25%) i ʻike i kahi hoʻemi kaumaha o ka liʻiliʻi he 15% mai ka papa kuhikuhi.
• Ua hōʻike ʻia ka loiloi multivariate o nā covariates baseline ua pili nui kēia mau mea ʻehiku me ≥15% pohō kaumaha: ʻoi aku ka nui o ka tirzepatide dose, he wahine, he lāhui keʻokeʻo a ʻAsia paha, ʻoi aku ka ʻōpio, e mālama ana me ka metformin, ʻoi aku ka maikaʻi o ka mana glycemic (ma muli o ma ka A1c haʻahaʻa a me ka glucose koko hoʻokē ʻai haʻahaʻa), a me ka haʻahaʻa haʻahaʻa o ka lipoprotein cholesterol kiʻekiʻe kiʻekiʻe.
• I ka wā o ka hahai ʻana, ua pili nui ka loaʻa ʻana o ka liʻiliʻi he 15% o ke kaumaha o ke kino me ka hoʻohaʻahaʻa nui ʻana i ka A1c, ka pae glucose koko hoʻokē ʻai, ka ʻāʻī o ka pūhaka, ke kahe koko, ka pae serum triglyceride, a me ka pae serum o ka enzyme alanine transaminase. .
  

  I KA HANA:

  Hiki i kēia mau ʻike ke hāʻawi i ka ʻike koʻikoʻi i nā kauka a me nā poʻe me ka maʻi maʻi type 2 e pili ana i ka hiki ke loaʻa i ka hōʻemi nui o ke kaumaha o ke kino me ka tirzepatide, a kōkua pū kekahi e hōʻailona i ka hoʻomaikaʻi ʻana e ʻike ʻia i loko o kahi ʻano o nā ʻāpana pilikia cardiometabolic me ka tirzepatide-induced weight loss. ," i hoʻopau ai nā mea kākau i kā lākou hōʻike.